Cantor 50pgs report just out: Tortoise and the Hare: Don't Underestimate PFE's Best-In-Class Hemophi | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  147722 of 148878  at  7/3/2020 4:05:34 AM  by

don1955


Cantor 50pgs report just out: Tortoise and the Hare: Don't Underestimate PFE's Best-In-Class Hemophilia Franchise

Based on our discussions with physicians, a considerable number of patients would wait to see PFE's Phase 3 data before deciding which gene therapy to use. This is because it is not clear if re-treatment is possible, even with a different therapy. PFE believes that its hemophilia A gene therapy may not show the attenuation seen by its competitor. PFE said this is because of the transient and moderate need for steroids in its patients as well as their robust durability of factor VIII, substantially above 50% of normal, which is distinct from competitor studies. 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 63     Views: 1391
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
147723 Re: Cantor 50pgs report just out: Tortoise and the Hare: Don't Underestimate PFE's Best-In-Class Hemophilia Franchise dnmun 9 7/3/2020 4:41:22 AM
147736 Re: Cantor 50pgs report just out: Tortoise and the Hare: Don't Underestimate PFE's Best-In-Class Hemophilia Franchise civic08801 1 7/5/2020 9:07:47 AM
147763 GUYS! FOCUS !!!! Don't Underestimate PFE's Best-In-Class Hemophilia Franchise don1955 4 7/6/2020 8:39:26 AM
147813 Re: Cantor 50pgs report just out: Tortoise and the Hare: Don't Underestimate PFE's Best-In-Class Hemophilia Franchise sangamo 10 7/7/2020 1:41:09 PM






Financial Market Data provided by
.


Loading...